絞り込み

16639

広告

「"Laeis P "[Author]」の検索結果

24件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design.

Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).

Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.

Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.

Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.

The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry.

The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.

Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF.

The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry.

Adding Hydrochlorothiazide to Olmesartan/Amlodipine Increases Efficacy in Patients With Inadequate Blood Pressure Control on Dual-Combination Therapy.

Efficacy and Tolerability of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: A Subgroup Analysis of Patients Stratified by Hypertension Severity, Age, Sex, and Obesity.

Open-Label Study Assessing the Long-term Efficacy and Safety of Triple Olmesartan/Amlodipine/Hydrochlorothiazide Combination Therapy for Hypertension.

Efficacy and Safety of Triple Antihypertensive Therapy with the Olmesartan/Amlodipine/Hydrochlorothiazide Combination.

Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study.

Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension.

Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension.

Clinical efficacy of olmesartan medoxomil.

Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist.

Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil.

  1. 1
  2. 2
Sort by
※並べ替えは表示に時間がかかります